

**Supplemental Table 1. Determinants of visceral adiposity**

Variable	Visceral Adiposity	
	Rho	P-value
<b>Demographics and clinical characteristics</b>		
Age, years	0.31	<0.001
Males	0.42	<0.001
Hypertension	0.30	<0.001
Hyperlipidemia	0.28	<0.001
Diabetes mellitus	0.19	<0.001
Lipid therapy	0.38	<0.001
Current smoker	-0.08	<0.001
Framingham risk score	0.55	<0.001
Body mass index	0.71	<0.001
Waist to hip ratio	0.54	<0.001
<b>Clinical and lab values</b>		
Systolic blood pressure, mm Hg	0.20	<b>0.001</b>
Diastolic blood pressure, mm Hg	0.17	<b>0.004</b>
Total cholesterol, mg/dL	-0.05	0.43
HDL cholesterol, mg/dL	-0.49	<0.001
LDL cholesterol, mg/dL	0.07	0.25
Triglycerides, mg/dL	0.46	<0.001
Cholesterol efflux capacity	-0.32	<0.001
hs-CRP, mg/L	0.31	<0.001
Fasting blood glucose, mg/dL	0.47	<0.001
Insulin	0.67	<0.001
HOMA-IR	0.66	<0.001
Erythrocyte sedimentation rate, mm/hr	0.15	<b>0.01</b>
GlycA, $\mu\text{mol/L}$	0.37	<0.001
Subcutaneous adiposity	0.50	<0.001
<b>Psoriasis characterization</b>		
Psoriasis area severity index score	0.17	<b>0.004</b>
Biologic therapy	-0.01	0.85
<b>Coronary artery characterization</b>		
Prevalent plaque	0.40	<0.001
Non-calcified coronary artery burden, mm <sup>2</sup>	0.55	<0.001
<b>NMR Parameters</b>		
LDL particle number	0.24	<0.001
Small LDL particle number	0.46	<0.001
Large LDL particle number	-0.24	<0.001
VLDL particle number	0.27	<0.001
Small VLDL particle number	0.004	0.95
Medium VLDL particle number	0.30	<0.001
Large VLDL particle number	0.51	<0.001

\*HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high sensitivity-C reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance; VLDL, very low-density lipoprotein; and PASI, psoriasis area severity index.

**Supplemental Table 2. Patient characteristics at baseline and one year**

Parameter	Baseline	One-year	P-value
<b>Demographics and medical history</b>	n=176	n=176	
Age, years	50.6 ± 12.5	51.7 ± 12.6	<b>&lt;0.001</b>
Males, n (%)	111 (63)	111 (63)	1.00
Hypertension, N (%)	48 (27)	48 (27)	<b>0.03</b>
Hyperlipidemia, N (%)	68 (39)	73 (41)	0.34
Type 2 diabetes mellitus, N (%)	13 (7)	14 (8)	0.66
Current tobacco use, N (%)	23 (13)	14 (8)	<b>0.01</b>
Lipid treatment, N (%)	51 (30)	54 (31)	0.41
Framingham risk score	2.3 (0.7-6.1)	2.3 (1.0-6.0)	0.92
Body mass index	28.8 (25.2-32.9)	28.4 (24.6-32.3)	0.52
<b>Clinical and laboratory values</b>			
Total cholesterol, mg/dL	184.9 ± 38.6	182.8 ± 38.3	0.20
HDL cholesterol, mg/dL	56.6 ± 19.4	57.3 ± 19.7	0.21
LDL cholesterol, mg/dL	103.9 ± 30.2	100.3 ± 32.6	0.05
Triglycerides, mg/dL	121.6 ± 74.5	127.2 ± 73.6	0.15
GlycA, µmol/L	399 (355-444)	382 (337-426)	<b>0.003</b>
hs-CRP, mg/L	1.8 (0.8-3.8)	1.5 (0.7-3.6)	0.07
<b>Psoriasis characterization</b>			
Psoriasis area severity index score	5.4 (3.0-10.0)	3.2 (1.5-5.5)	<b>&lt;0.001</b>
Biologic therapy, N (%)	60 (34)	102 (58)	<b>&lt;0.001</b>
<b>Adipose characterization</b>			
Visceral adiposity (cc <sub>3</sub> )	15883.9 ± 9306.9	15817 ± 9253.0	0.38
Subcutaneous adiposity (cc <sub>3</sub> )	19030.5 ± 10796.4	18830.0 ± 10276.8	0.21
<b>Coronary Artery Characterization</b>			
Total coronary burden, mm <sup>2</sup>	1.25 ± 0.55	1.24 ± 0.56	0.29
Non-calcified coronary artery burden, mm <sup>2</sup>	1.19 ± 0.53	1.17 ± 0.56	0.27
Plaque Present (%)	86 (49)	91 (52)	0.17
<b>NMR Parameters</b>			
HDL particle number	33.8 (30.7-39.5)	34.7 (31.0-39.1)	0.27
Small HDL particle number	19.8 (14.7-23.6)	20.0 (14.5-24.5)	0.78
Medium HDL particle number	7.6 (4.6-12.4)	8.1 (3.9-13.1)	0.34
Large HDL particle number	5.4 (3.0-8.4)	5.6 (3.3-8.7)	0.06
LDL particle number	1156 (897-1484)	1165 (909-1449)	0.73
Small LDL particle number	455 (311-684)	479 (278-696)	0.68
Large LDL particle number	339 (203-523)	403 (216-536)	0.36
VLDL particle number	41.8 (24.1-62.3)	45.6 (30.0-63.1)	0.19
Small VLDL particle number	20.7 (11.6-33.8)	23.8 (14.0-36.9)	<b>0.02</b>
Medium VLDL particle number	14.6 (6.8-25.6)	12.8 (5.4-24.9)	0.26
Large VLDL particle number	2.5 (1.2-5.7)	3.4 (2.0-6.5)	<b>&lt;0.001</b>

\* HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high sensitivity-C reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance; VLDL, very low-density lipoprotein; and PASI, psoriasis area severity index.

**Supplemental Table 3. Patient characteristics at baseline and four-years**

Parameter	Baseline	Four-year	P-value
<b>Demographic and Clinical Characteristics</b>	n=50	n=50	
Age, years	51.9 ± 12.0	56.2 ± 11.9	<b>&lt;0.001</b>
Males	29 (58)	29 (58)	1.00
Hypertension	17 (34)	12 (24)	0.10
Hyperlipidemia	28 (56)	21 (42)	<b>0.03</b>
Type-2 diabetes	5 (10)	3 (6)	0.32
Current smoker	6 (12)	7 (14)	0.65
Statin use	17 (34)	20 (40)	0.18
<b>Clinical and Lab Values</b>			
Total cholesterol, mg/dL	181.1 ± 43.4	181.0 ± 44.2	0.99
HDL cholesterol, mg/dL	53.6 ± 20.4	54.9 ± 18.5	0.42
LDL cholesterol, mg/dL	102.3 ± 32.6	97.8 ± 35.2	0.38
Triglycerides, mg/dL	130.8 ± 99.1	144.4 ± 92.3	0.44
Framingham risk score	4 (1-7)	4 (1-8)	0.57
hs-CRP, mg/L	1.8 (1.0-4.2)	2.1 (0.6-4.8)	0.78
Body Mass Index (BMI)	29.0 (26.1-35.7)	29.6 (25.8-33.0)	0.48
Glucose, mg/dL	99.0 ± 16.9	106.1 ± 33.8	0.04
Insulin, mg/dL	15.1 ± 8.9	15.7 ± 13.5	0.71
HOMA-IR	3.3 (1.7-4.6)	2.9 (1.7-5.4)	0.87
Visceral Adiposity (cm <sup>3</sup> )	17986 ± 8978	18188 ± 8298	0.37
Subcutaneous Adiposity (cm <sup>3</sup> )	21304 ± 12345	20937 ± 11040	0.26
Total Adiposity (cm <sup>3</sup> )	39290 ± 18376	39125 ± 16012	0.44
<b>Psoriasis Severity</b>			
PASI Score	4.0 (1.8-7.7)	1.6 (0.9-3.6)	<b>0.003</b>
Biologic treatment	23 (46)	29 (58)	<b>0.004</b>
<b>Coronary Characterization</b>			
Non-calcified coronary artery burden, mm <sup>2</sup>	1.24 ± 0.56	1.25 ± 0.49	0.37
Plaque Present (%)	28 (56)	29 (58)	0.56

\* HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; hs-CRP, high sensitivity-C reactive protein; HOMA-IR, homeostatic model assessment of insulin resistance; VLDL, very low-density lipoprotein; and PASI, psoriasis area severity index.